Key result
A single dose of inactivated poliovirus vaccine administered to 5-month-old children achieved >95% type 2 antibody seroprevalence at 1 month, successfully closing the immunity gap.
Why the study?
Does inactivated poliovirus vaccine (IPV) improve type 2 antibody seroprevalence in 5-month-old children?
Does inactivated poliovirus vaccine (IPV) improve type 2 antibody seroprevalence in 5-month-old children?
One dose of IPV successfully closed the type 2 immunity gap in 5-month-old children in Vietnam.
Hypothesis-generating for single-dose IPV schedules in infants; prospective trials needed before clinical adoption.
This was a cross-sectional community-based serological survey of polio antibodies assessing the immunogenicity of inactivated poliovirus vaccine (IPV) focusing on poliovirus serotype 2. IPV was administered to 5-month-old children. Type 2 antibody seroprevalence when measured 1 month after IPV administration was >95%. One IPV dose successfully closed the immunity gap.
No takes yet. Share an insight, caveat, or question.
Huyền et al. (2022) studied this question. A single dose of inactivated poliovirus vaccine administered to 5-month-old children achieved >95% type 2 antibody seroprevalence at 1 month, successfully closing the immunity gap.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: